期刊文献+

原发性肾脏病患者糖皮质激素性骨质疏松的发生及预防治疗情况 被引量:3

State and prevention of glucocorticoid - induced osteoporosis in patients with primary glomerulonephritis
下载PDF
导出
摘要 目的了解原发性肾小球疾病患者糖皮质激素性骨质疏松的发病及预防治疗情况。方法记录应用糖皮质激素(GC)的原发性肾小球疾病患者的年龄、性别、体重指数、吸烟史、应用 GC的时间、累积剂量、骨质疏松预防治疗用药情况;测定腰椎和股骨颈骨密度。结果 123例病人中骨质异常(骨量减少和骨质疏松)者82例(66.7%),骨密度正常者41例(33.3%)。腰椎骨密度随GC的累积剂量的增加而逐渐下降,服用GC>1个月的各组与<1个月组相比腰椎骨密度下降明显(P<0.05),>12个月者与1-<3个月者相比腰椎骨密度下降显著(P<0.05)。只有43例患者能规律服用维生素D加钙剂,在服用GC累积剂量及时间无差异的条件下,规律服用维生素D 加钙剂组骨质异常发生率(34.9%)明显低于单纯服用钙剂组(78.2%)及不用药组(73.4%),P< 0.05。结论原发性肾小球疾病应用GC患者骨密度随GC的累积剂量增加而逐渐下降,GC的累积剂量及未预防应用维生素D及钙剂是骨密度下降的危险因素。 Objective To investigate the state of glucocorticold (GC) - induced osteoporosis (GIOP) and the current prevention of GIOP in patients with primary glomerulonephritis. Methods Primary glomerulonephritis patients receiving GC therapy were observed and bone mineral density (BMD) in the lumbar spine and the femoral neck were measured. Age, sex, body - mass - index, smoking history, the time and accumulative dose of GC treatment, and the state of osteoporosis prevention were investigated, the factors that influence the BMD were analyzed. Results A total of one hundred and twenty - three patients were included in this study. Among them, osteoporosis and osteopenia were found in 82 patients (66.7%). Lumbar spine BMD decrease gradually with the increase of the accumulative dose of GC. There were statistical differences in the BMD of lumbar spine in patients with receving GC at the period of less than 1 month compared with other groups( 1 - 〈 3, 3- 〈 6, 6-〈 9, 9- 〈 12, 〉 12 months) ( P 〈 0.05). Among 123 patients, only 43 patients took vitamin D and agent containing calcium regularly, but the incidence of abnormal BMD in this group was significant de- creased compared with other only taking agent containing calcium and without treatment at the same state of CA2 treatment period and accumulative dose (P 〈 0.05). Conclusion BMD in patients with primary glomerulonephritis receiving GC therapy decrease gradually with the incresse of accumulative dose of GC. Accumulative dose of GC and without receiving osteoporosis prevention therapy were risk factors of abnormality of BMD.
作者 陈航 王梅
出处 《中国医师进修杂志(内科版)》 2006年第3期15-17,共3页 Chinese Journal of Postgraduates of Medicine
基金 北京大学"十五""211"工程-循证医学学科群课题项目(91000-246156061)
关键词 原发性肾小球疾病 糖皮质激素性骨质疏松 骨密度 Primary glomerulonephritis Glucocorticoid -induced osteoporosis Bone mineral density
  • 相关文献

参考文献7

  • 1Fujita T, Satomura A, Hidaka M, et al.Acute alteration in bone mineral density and blochemical markers for bone metaholism in nephritic patients receiving high- dose glucocorticoid and one-cycle etidronate therapy. Calcif Tissue Int, 2000,66:195 - 199.
  • 2Lange U, Boss B, Teichmann J, et al. Bone mineral density and biochemical makers of bone metabolism in late onset rheumatoid arthritis and polymyalgia rheumatoid- a prospective study on the influence of glucocorticoid therapy, Z Rheumatol,2000,59 (Suppl 2): 137- 141.
  • 3MeKenzie R, Reynolds JC, O'Fallon A, et al. Decresed hone mineral during low dose glucocorticoid administration in a randomised-placebo controlled trial. J Rheumatol, 2000,27: 2222 - 2225.
  • 4Adachi J, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid - induced osteoporosis. N Engl J Med, 1997,337 : 382 - 387.
  • 5Boutsen Y, Jamart J, Esselinckx W, et al. Primary prevention of glucocorticoid- induced osteoporosis with intermittent intracenous pamidronate:a randomized trial. Calcif Tissue Int, 1997,61:266 - 271.
  • 6Cohen S, Levy RM, Keller M, et al.Risedronate therapy prevents corticosteroids-induced bone loss. Arthritis Rheum, 1999, 42:2309 -2318.
  • 7Ringe JD, Dorst A, Faber H, et al. Superiority of alfacalcidol over vitamin D in the treatment of glucocorticoid - induced osteoporosis.Rheumatol Int, 2004,24 : 63 - 70.

同被引文献16

  • 1陈航,王梅.原发性肾小球疾病应用糖皮质激素患者骨密度情况及骨质疏松预防现状[J].中华肾脏病杂志,2005,21(11):695-696. 被引量:6
  • 2李子荣.晚期股骨头坏死的人工关节置换术[J].中国医师进修杂志(外科版),2006,29(7):3-6. 被引量:5
  • 3糖皮质激素性骨质疏松症诊疗指南(讨论稿)[J].中华全科医师杂志,2006,5(8):460-461. 被引量:27
  • 4戴滨.糖皮质激素性骨质疏松症的发病机制及其防治措施[J].天津药学,2006,18(5):49-52. 被引量:4
  • 5Vidal NO,Brandstrom H,Jonsson KB.et al.Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells:down-regulation by glucocorticoids.J Endocrinol,1998,159(1):191-195.
  • 6Sugano N,Kubo T,Takaoka K,et al.Diagnostic criteria for nontraumatic osteonecrosis of the femoral head.A multicentre study.J Bone Joint Surg Br,1999,81(4):590-595.
  • 7Valimaki MJ.Kinnunen K,Volin L,et al.A prospective study of bone loss and turnover after allo geneic bone marrow transplantation:effect of calcium supplementation with or without calcitonin.Bone Marrow Transplant,1999,23(4):355-361.
  • 8Atkinson K,Cohen M,Biggs J,et al.Avasculsr necrosis of the femond head secondary to corticosteroid therapy for graft-versus-host disease after marrow transplantation:effective therapy with hip arthroplasty.Bone Marrow Transplant,1987,2(4):421-426.
  • 9Vitovski S,Phillips JS,Sayers J,et al.Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand:evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways.J Biol Chem,2007,282(43):31601-31609.
  • 10叶任高;陆再英.内科学[M]北京:人民卫生出版社,2004508-516.

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部